Imatinib may be ABL to improve anti-angiogenic therapy

We recently reported that neuropilin 1 (NRP1) drives angiogenesis by promoting extracellular matrix signaling in endothelial cells via ABL1 kinase. Imatinib targets this pathway in pathological angiogenesis and may provide a novel opportunity for anti-angiogenic therapy of age-related macular degene...

Descripción completa

Detalles Bibliográficos
Autores principales: Raimondi, Claudio, Fantin, Alessandro, Ruhrberg, Christiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905228/
https://www.ncbi.nlm.nih.gov/pubmed/27308396
http://dx.doi.org/10.4161/23723548.2014.968034
_version_ 1782437232136683520
author Raimondi, Claudio
Fantin, Alessandro
Ruhrberg, Christiana
author_facet Raimondi, Claudio
Fantin, Alessandro
Ruhrberg, Christiana
author_sort Raimondi, Claudio
collection PubMed
description We recently reported that neuropilin 1 (NRP1) drives angiogenesis by promoting extracellular matrix signaling in endothelial cells via ABL1 kinase. Imatinib targets this pathway in pathological angiogenesis and may provide a novel opportunity for anti-angiogenic therapy of age-related macular degeneration, proliferative diabetic retinopathy, or solid tumor growth.
format Online
Article
Text
id pubmed-4905228
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49052282016-06-15 Imatinib may be ABL to improve anti-angiogenic therapy Raimondi, Claudio Fantin, Alessandro Ruhrberg, Christiana Mol Cell Oncol Commentary We recently reported that neuropilin 1 (NRP1) drives angiogenesis by promoting extracellular matrix signaling in endothelial cells via ABL1 kinase. Imatinib targets this pathway in pathological angiogenesis and may provide a novel opportunity for anti-angiogenic therapy of age-related macular degeneration, proliferative diabetic retinopathy, or solid tumor growth. Taylor & Francis 2015-02-24 /pmc/articles/PMC4905228/ /pubmed/27308396 http://dx.doi.org/10.4161/23723548.2014.968034 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Commentary
Raimondi, Claudio
Fantin, Alessandro
Ruhrberg, Christiana
Imatinib may be ABL to improve anti-angiogenic therapy
title Imatinib may be ABL to improve anti-angiogenic therapy
title_full Imatinib may be ABL to improve anti-angiogenic therapy
title_fullStr Imatinib may be ABL to improve anti-angiogenic therapy
title_full_unstemmed Imatinib may be ABL to improve anti-angiogenic therapy
title_short Imatinib may be ABL to improve anti-angiogenic therapy
title_sort imatinib may be abl to improve anti-angiogenic therapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905228/
https://www.ncbi.nlm.nih.gov/pubmed/27308396
http://dx.doi.org/10.4161/23723548.2014.968034
work_keys_str_mv AT raimondiclaudio imatinibmaybeabltoimproveantiangiogenictherapy
AT fantinalessandro imatinibmaybeabltoimproveantiangiogenictherapy
AT ruhrbergchristiana imatinibmaybeabltoimproveantiangiogenictherapy

Ejemplares similares